Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Combinations for IBS-D
NCT05867550Phase 4Completed
- Sponsor
- Bahria University
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mebeverine, amitriptyline, psyllium husks in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by Bahria University. Started Jan 2023; status: completed.
02
Drugs
mebeverineamitriptylinepsyllium husks
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05867550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867550.